araag2/HINT huggingface dataset:
Clinical trial NCT00006032 (phase 2, status: terminated)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: etoposide, ifosfamide, topotecan hydrochloride
SMILES: OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, N[C@@H](CCCNC(N)=N)C(O)=O, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O
Reason stopped: 
    low accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS: Histologically confirmed metastatic breast cancer that has
        demonstrated at least partial response to any salvage regimen Partial response defined as
        at least 50% reduction in measurable or evaluable disease for at least 4 weeks, no disease
        progression, no new lesions, or bone lesions that remain static for at least 8 weeks with
        an improvement in pain symptoms No more than 3 organs involved with metastatic disease No
        prior or active CNS involvement Hormone receptor status: Not specified

        PATIENT CHARACTERISTICS: Age: 18 to 64 Sex: Female Menopausal status: Not specified
        Performance status: ECOG 0-1 Life expectancy: Not specified Hematopoietic: Not specified
        Hepatic: Bilirubin no greater than 2.0 mg/dL SGOT or SGPT no greater than 2.5 times upper
        limit of normal No history of severe hepatic dysfunction Renal: Creatinine no greater than
        2.0 mg/dL OR Creatinine clearance at least 60 mL/min Cardiovascular: No severe cardiac
        dysfunction Ejection fraction at least 50% by MUGA No major heart disease Controlled
        hypertension allowed Pulmonary: DLCO at least 50% of normal OR No symptomatic obstructive
        or restrictive disease Other: Not pregnant or nursing Negative pregnancy test Fertile
        patients must use effective barrier contraception No uncontrolled insulin dependent
        diabetes mellitus No uncompensated major thyroid or adrenal dysfunction No significant skin
        breakdown from tumor or other disease No other prior malignancy in past 5 years except
        nonmelanoma skin cancer or carcinoma in situ of the cervix No active infections HIV
        negative

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease
        Characteristics No more than 2 prior salvage regimens for metastatic disease No prior
        topotecan Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not
        specified Other: No concurrent nitroglycerin preparations for angina No concurrent
        antiarrhythmics for major ventricular arrhythmias
Clinical trial NCT00262925 (phase 2, status: terminated)
Conditions: recurrent adult acute lymphoblastic leukemia
ICD codes: C83.57, C83.50, C91.01, C91.02, C83.52, C83.56, C83.53
Drugs: asparaginase, methotrexate, dexamethasone, leucovorin calcium, mercaptopurine, vincristine
SMILES: N[C@@H](CC(O)=O)C(O)=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, S=C1N=CNC2=C1NC=N2, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Refractory or relapsed acute lymphoblastic leukemia

               -  Must be in first relapse or have failed to achieve complete remission with 1
                  prior regimen

          -  Prior central nervous system (CNS) leukemia allowed provided cerebrospinal fluid is
             normal

          -  ECOG Performance status of 0-3

          -  Bilirubin normal

          -  Creatinine normal

          -  Human immunodeficiency virus (HIV) negative

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        Exclusion criteria:

          -  Hepatitis B positivity

          -  Bacterial or fungal infection

          -  Infection requiring treatment with antibiotics

          -  Active cytomegalovirus infection by molecular detection methods

          -  Known hypersensitivity to alemtuzumab or its components

          -  Pregnant or nursing

          -  Other malignancy within the past 5 years except adequately treated basal cell skin
             cancer or cervical carcinoma
Clinical trial NCT00281021 (phase 2, status: terminated)
Conditions: carcinoma, non-small cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: erlotinib plus digoxin
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
Reason stopped: 
    interim analysis revealed that only 1 patient had a partial response.
  
Eligibility criteria:

        Inclusion Criteria:

          -  diagnosis of non-small cell lung cancer

          -  measurable or evaluable disease

          -  primary tumor must be documented by histopathic analysis

          -  disease recurrences occurring greater than five years after original diagnosis must be
             biopsy proven

          -  treatment with only one prior chemotherapy regimen for advanced disease (one
             additional prior regimen was allowed for neoadjuvant, adjuvant, or neoadjuvant plus
             adjuvant therapy)

          -  serum creatinine < 2mg/dl, or a calculated creatinine clearance > 40cc/min using the
             following formula: (140-age) x WT(kg) x 0.85 (if female 0.72) x creatinine (mg/dl).
             Tests must be done within 28 days prior to registration

          -  must have a CT scan (chest & abdomen) within 4 weeks prior to registration

          -  Zubrod performance status of 0-3

        Exclusion Criteria:

          -  women who are pregnant or nursing

          -  no other prior malignancy is allowed except for: adequately treated basal cell or
             squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II
             cancer from which the patient is currently in complete remission, or any other cancer
             from which the patient has been disease-free for 5 years

          -  history of ventricular fibrillation, sinus node or AV nodal disease, Wolff Parkinson
             White Syndrome, evidence of congestive heart failure, chest pain with exertion,
             hemodynamically significant or life threatening cardiac arrhythmia, or evidence of
             prior myocardial infarction on EKG. EKG must have been done within 28 days prior to
             registration. A normal cardiac stress test within 182 days prior to registration is
             required for all patients over 50 years old or those with abnormal EKG or any history
             of cardiac disease.

          -  hypersensitivity to erlotinib and/or Digoxin

          -  abnormal levels of K, Mg, and/or Ca, or conditions which cause such abnormalities
             (e.g. malnutrition, severe diarrhea, prolonged vomiting, dialysis, GI suction,
             untreated hypothyroidism, and use of diuretics, amphotericin B, steroids, or antacids)
Clinical trial NCT01674062 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: pertuzumab, trastuzumab
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Females greater than or equal to (≥) 18 years of age, with histologically-confirmed
             HER2-positive breast cancer

          -  Metastatic breast cancer, with progression on trastuzumab-based therapy as last
             treatment for metastatic disease

          -  Less than or equal to (≤) 3 chemotherapy regimens prior to study entry

          -  Last trastuzumab dose ≤9 weeks before study entry for participants receiving
             pertuzumab + trastuzumab, and ≥4 weeks for participants receiving pertuzumab
             monotherapy

          -  Left ventricular ejection fraction ≥55% at study entry

        Exclusion Criteria:

          -  Previous treatment with an anti-cancer vaccine or any targeted therapy other than
             trastuzumab

          -  Brain metastases

          -  History of any cardiac adverse event related to trastuzumab therapy

          -  Any other malignancy in the last 5 years, except for basal cell cancer or cancer in
             situ of the cervix
Clinical trial NCT00537407 (phase 2, status: completed)
Conditions: chronic hepatitis c
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: debio 025, peg-ifnα2a, ribavirin
SMILES: CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(CC)C(=O)[C@@H](C)N(C)C1=O)C(C)C, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female patients between 18 and 60 years of age.

          -  Hepatitis B negative and human immunodeficiency virus (HIV) negative.

          -  Diagnosed with hepatitis C genotype I and not responsive to treatments such as
             peginterferon alpha-2a or 2b and ribavirin for at least 12 weeks.

          -  Adequate liver function (Child-Pugh-Turcotte score A) and other laboratory parameters
             within acceptable range.

          -  Females may participate only if they cannot become pregnant, i.e., are surgically
             sterile, post-menopausal, or using 2 reliable contraceptive methods.

          -  Male patients must be surgically sterile or utilizing a barrier contraceptive method.

          -  For female patients of child bearing potential, negative pregnancy test within 1 week
             of first investigational product administration.

        Exclusion Criteria:

          -  Treatment with any investigational drug within 6 months prior to the start of the
             study.

          -  Ongoing or recent use of antiviral medication within 1 month before the start of the
             study.

          -  A known bad reaction or intolerance to Debio 025, peginterferon alpha-2a, and/or
             ribavirin.

          -  Presence or history of any severe related disease.
Clinical trial NCT00707239 (phase 2, status: terminated)
Conditions: pneumonia, bacterial
ICD codes: J15.9, P23.6
Drugs: tigecycline, tigecycline, imipenem/cilastatin
SMILES: [H][C@@]12CC3=C(C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C, [H][C@@]12CC3=C(C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C, CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O
Reason stopped: 
    see termination reason in detailed description.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects, greater than or equal to 18 years of age, known or suspected
             to have acute hospital-acquired pneumonia (HAP).

          -  Acute HAP is defined as pneumonia with onset of symptoms:

               1. Greater than or equal to 48 hours after admission to an acute care hospital or
                  chronic care facility such as a skilled nursing home facility or rehabilitation
                  unit. Or

               2. Less than or equal to 7 days after the subject was discharged from the hospital.
                  The initial hospitalization must have been greater than or equal to 3 days
                  duration.

          -  VAP is defined as: onset of symptoms of pneumonia greater than or equal to 48 hours
             after endotracheal intubation.

          -  Presence of a new or evolving infiltrate on a chest x-ray film, presence of fever or
             leukocytosis, respiratory failure requiring mechanical ventilation or presence of 2 of
             the following clinical signs and symptoms: cough, dyspnea or tachypnea, pleuritic
             chest pain, rales and/or evidence of pulmonary consolidation, hypoxemia, or purulent
             sputum production.

        Exclusion Criteria:

          -  Subjects with other significant underlying conditions that would make it difficult to
             evaluate the subjects or make it unlikely to complete the therapy or that would
             increase their risk by participating in the study, infection with organisms known to
             be resistant, contraindication, or hypersensitivity to any of the test articles.
Clinical trial NCT00595426 (phase 2, status: completed)
Conditions: arthroplasty, replacement, knee
ICD codes: Z79.890, Z96.693, Z47.1, Z95.4, Z96.691, Z96.692, T82.320S
Drugs: ym150, warfarin
SMILES: COC1=CC=C(C=C1)C(=O)NC1=C(NC(=O)C2=CC=C(C=C2)N2CCCN(C)CC2)C(O)=CC=C1, S1SSSSSSS1
Eligibility criteria:

        Inclusion Criteria:

          -  Subject is scheduled for elective primary knee arthroplasty

          -  Written Informed consent obtained

        Exclusion Criteria:

          -  Subject has documented history of previous VTE

          -  Subject is considered to be at increased risk of VTE

          -  Subject has active bleeding or any condition associated with increased risk of
             bleeding

          -  Subject is planning to have surgery on the contralateral knee at the same time or
             within 6 weeks after enrollment into the study
Clinical trial NCT01437878 (phase 2, status: terminated)
Conditions: chronic obstructive pulmonary disease, pulmonary hypertension
ICD codes: J44.9, J44.1, J44.0, I27.0, I27.20, I27.21, I27.24, I27.29, P29.30, I27.22
Drugs: iloprost, placebo
SMILES: [H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    low recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          1. Signed informed consent prior to initiation of any study mandated procedure

          2. Male or female ≥ 40 and ≤ 75 years of age

          3. Women of childbearing potential1 must use a reliable method of contraception

          4. Clinical diagnosis of moderate to severe COPD, with an obstructive pattern on
             pulmonary function tests

          5. Current or past smokers of ≥ 10 pack years

          6. Ability to perform exercise testing without supplemental oxygen (in the best opinion
             of the investigator)

          7. Confirmed pulmonary hypertension by right heart catheterization (RHC)

        Exclusion Criteria:

          1. Other causes of pulmonary hypertension than COPD

          2. BMI > 35 kg/m2

          3. Conditions considered as contraindications for cardiopulmonary exercise testing (CPET)
             and/or inability to pedal on a cycle ergometer

          4. Pregnant or nursing

          5. Currently (within 30 days prior to RHC) taking specific pulmonary arterial
             hypertension (PAH) therapy (e.g., bosentan, ambrisentan, tadalafil, sildenafil,
             epoprostenol, treprostinil, iloprost, beraprost)

          6. Participation in any other clinical trial, except observational, or receipt of an
             investigational product within 30 days prior to RHC visit

          7. Known concomitant life-threatening disease with a life expectancy < 12 months

          8. Known hypersensitivity to iloprost or any of the excipients of the drug formulations
Clinical trial NCT00515112 (phase 2, status: terminated)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: androgel, placebo
SMILES: [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    this study has been terminated due to poor accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Prostate cancer

          -  Patient must have received primary definitive local therapy to the prostate (surgery
             and/or radiotherapy)

          -  Patient was surgically or pharmacologically castrated at least 6 months prior to
             starting the study

          -  Patient must have had a previous trial of anti-androgen therapy

          -  Patient must have a rising PSA

          -  No evidence of distant metastatic disease

          -  ECOG performance status < 2

          -  Age >18 years

          -  Patients must have normal hepatic function

        Exclusion Criteria:

          -  Patients with a history of any previous cytotoxic therapy or radionuclide therapy
             (such as rhenium, strontium, or samarium)

          -  Patients may not be receiving any other investigational agents

          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris,
             uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would
             limit compliance with study requirements

          -  Patients receiving renal dialysis

          -  Patients with significant pulmonary disease who have received chronic or pulse steroid
             therapy within the last 3 months prior to randomization will be excluded

          -  Patients who have known hypersensitivity to any of the AndroGel ingredients, including
             testosterone that is chemically synthesized from soy
Clinical trial NCT00038571 (phase 2, status: completed)
Conditions: lymphoma, b-cell
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: ps341 (bortezomib)
SMILES: CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
Eligibility criteria:

        INCLUSION:

          -  Relapsed or Refractory B cell lymphoma.

          -  Zubrod status </= 3.

          -  Measurable disease.

          -  No anti-cancer treatment within past 3 weeks.

          -  ANC >= 1500/uL, Plt >/= 50,000, Bilirubin <2 mg/dL, SGPT <2.5xULN, creatinine <2.
             Patients with ANC>/1000, PLT>/30000 will be eligible if due to massive splenomegaly
             and/or BM involvement.

          -  HIV negative.

          -  No active CNS lymphoma.

          -  No serious intercurrent illness, active infections or cancer except basal cell
             carcinoma of the skin or in situ cervical carcinoma.

          -  Not eligible for treatment of a higher priority. Patients may be entered before BMT.

          -  No pregnancy & age bearing females must be practicing adequate contraception.

          -  Age > 16.

        EXCLUSION:

          -  Patients with platelets <30x10(9)/L within 14 days before enrollment.

          -  Patients with ANC<1.0 x10(9)/L within 14 days before enrollment.

          -  Patients with peripheral neuropathy >/= grade 3 within 14 days before enrollment.
Clinical trial NCT01340053 (phase 2, status: completed)
Conditions: constipation predominant irritable bowel syndrome
ICD codes: K59.00, K59.09, K59.01, K59.02, K59.03, K59.04, K58.1
Drugs: rdx5791
SMILES: CN1C[C@@H](C2=CC(=CC=C2)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)C2=CC(=CC=C2)[C@@H]2CN(C)CC3=C2C=C(Cl)C=C3Cl)C2=C(C1)C(Cl)=CC(Cl)=C2
Eligibility criteria:

        Inclusion Criteria:

          -  Subject meets Rome III criteria for IBS-C

          -  If > 50 years old, colonoscopy evaluation within 10 years

          -  All ages, negative colonoscopy if any "warning symptoms"

          -  Active disease during 2-week screening period

          -  Compliant with IVRS

        Exclusion Criteria:

          -  Subjects has IBS-D, IBS-M or un-subtyped IBS according to Rome III criteria

          -  Diagnosis or treatment of any clinically symptomatic biochemical or structural
             abnormality of the GI tract

          -  Use of medications that are known to affect stool consistency

          -  Subject has any protocol-excluded or clinically significant medical or surgical
             history that could confound the study assessments or prevent completion of study
Clinical trial NCT00459901 (phase 2, status: terminated)
Conditions: metastatic colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: erlotinib and capecitabine
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
Reason stopped: 
    study halted by drug manufacturer
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who have histologically or cytologically confirmed diagnosis of metastatic
             colorectal adenocarcinoma.

          -  Patients must be > 18 years old.

          -  Patients must have a performance status of > 60 on the Karnofsky scale

          -  Patients must have an expected life expectancy of at least 12 weeks.

          -  Patients must give written informed consent as per institutional and federal
             regulatory requirements.

          -  Patients must have measurable or evaluable disease .

          -  Patients must have an absolute neutrophil count of > 1,500/mm3 and a platelet count >
             100,000/mm3.

          -  Patients must have adequate liver and renal function defined by a bilirubin of < 2.0
             mg/dl and a creatinine of < 1.5 mg/dl, respectively.

          -  Patients must be able to stay in the general area for the duration of their treatment
             on this clinical research study.

        Exclusion Criteria:

          -  Prior chemotherapy, treatment with inhibitors of EGFR of any kind, molecularly
             targeted

          -  Pregnant or lactating women

          -  Clinical signs of brain involvement or leptomeningeal disease

          -  Serious illness or medical conditions

          -  Congestive heart failure or unstable angina pectoris, uncontrolled hypertension or
             arrhythmias

          -  Active infections

          -  UnstaOphthalmic disorders that might increase the risk for epithelium related
             complications (bullous keratopathy, aniridia, severe chemical burns, neutrophilic
             keratitis e.g.)

          -  GI tract disease resulting in an inability to take oral medication such as
             uncontrolled inflammatory GI disease (e.g. Crohn's disease, ulcerative colitis) or
             post surgical malabsorption characterized by uncontrolled diarrhea that results in
             weight loss and vitamin deficiency orequires IV hyperalimentation (however, use of
             pancreatic enzyme supplementation is allowed provided that the above criteria are not
             met).

          -  Prior invasive malignancies for less 5 years

          -  Known to be HIV positive.
Clinical trial NCT00240734 (phase 2, status: terminated)
Conditions: anemia
ICD codes: D53.2, D64.9, D46.4, D53.0, D53.9, D61.3, D61.9
Drugs: epoetin alfa
SMILES: OC(=O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O
Reason stopped: 
    this study was stopped for slow enrollment after enrolling only 11 of 180 patients in six
    months time.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with a clinical diagnosis of diabetes mellitus

          -  History of documented proteinuria or microalbuminuria

          -  A glomerular filtration rate between 15 and 90 mL/minute/1.73m2

          -  Subjects with hemoglobin greater than or equal to 9.0 /dL and less than or equal to
             11.0 g/dL.

        Exclusion Criteria:

          -  A current diagnosis of poorly controlled high blood pressure (hypertension) (systolic
             blood pressure > 150 mm Hg or diastolic blood pressure > 100 mm Hg) after adequate
             anti hypertensive therapy

          -  Subjects with severe neuropathy or peripheral vascular disease with gait instability

          -  Subjects scheduled to receive dialysis during the course of the study

          -  Subjects with a transferrin saturation < 20% or ferritin level < 50 ng/dL

          -  Subjects with active malignancy, defined as a malignancy requiring current therapy
             (surgery, chemotherapy, or radiotherapy) or a history of treatment for malignancy in
             the last 5 years.